Predictors of Rapid, Complete Skin Clearance With Psoriasis Biologics

New real-world research is shedding light on which patients with psoriasis are most likely to experience rapid and sustained complete skin clearance when treated with biologic therapies, an outcome increasingly referred to as “early super-response” (ESR).¹

The concept of ESR is gaining traction in dermatology as a meaningful clinical goal. Unlike traditional response metrics, which often focus on outcomes at 12 or 24 weeks, ESR emphasizes both speed and durability, factors that may influence long-term treatment success, patient satisfaction, and healthcare utilization. Experts note that early response may also serve as a predictor of sustained benefit, helping guide treatment decisions such as dose adjustments or therapy continuation.

In the new study, researchers analyzed 299 adults with moderate-to-severe psoriasis receiving biologic therapy in a real-world clinical setting. ESR was defined as achieving complete skin clearance (PASI 100) as early as week 4 and maintaining near-complete clearance (PASI <1) through week 48, a stringent benchmark that reflects both speed and durability of response. The findings were recently published in Clinical, Cosmetic and Investigational Dermatology.

More than three-quarters of patients (76.3%) met the ESR benchmark, underscoring the effectiveness of modern biologic therapies. Among the strongest predictors of ESR was whether patients were biologic-naïve. Patients new to biologics were more than twice as likely to achieve early super-response compared with those who had prior exposure (OR, 2.16; 95% CI, 1.17–3.96, P = .013). This finding aligns with previous research suggesting that earlier use of advanced therapies may yield better outcomes.

Interestingly, the type of biologic therapy itself did not independently predict ESR when controlling for other factors. Across major classes, including IL-17, IL-23, and TNF inhibitors, no significant differences were observed in overall ESR rates. However, some variability was noted at the individual drug level. For example, ixekizumab (Taltz; Eli Lilly) appeared to be associated with higher rates of early response, while guselkumab (Tremfya; Johnson & Johnson) showed lower rates in this cohort, though these findings were considered exploratory.

A key predictive marker identified by the researchers was baseline inflammation. Patients with higher neutrophil counts were significantly more likely to achieve rapid and sustained clearance (OR, 1.26; 95% CI, 1.04–1.53; P = .016). Patients considered early super-responders had higher median neutrophil levels compared with non-responders, supporting the idea that patients with more active inflammatory disease may respond more robustly to targeted immune therapies.

Conversely, certain disease characteristics appeared to hinder early response. For example, psoriasis affecting the palms of the hands and soles of the feet emerged as a strong negative predictor (OR = 0.27, 95% CI 0.13–0.58, P = .001). This difficult-to-treat phenotype was significantly more common among patients who did not achieve early super-response (25.4% vs. 7.9%; P < .001).

“Consistent with our findings, a study assessing bimekizumab response reported that palmoplantar involvement not only negatively affected the PASI 100 response at week 4, but was also associated with lower PASI 75 and PASI 90 responses at the same time point,” described the researchers. Patients with this subtype have also reported greater use of topical prescriptions and worse quality of life.²

Lifestyle factors may also play a role, suggested the new study findings. Smoking showed a borderline negative association with treatment success, suggesting that patients with a history of smoking may be less likely to achieve rapid clearance, though the finding did not reach statistical significance (P = .055).

Beyond clinical characteristics, the study also explored laboratory markers of systemic inflammation. In addition to neutrophil count, the platelet-to-lymphocyte ratio (PLR) showed a borderline positive association with early response. These findings suggest that readily available blood-based biomarkers could help clinicians identify patients more likely to benefit from biologic therapy.

The researchers recognized several limitations of their study, including its retrospective design and single-center setting, which may limit generalizability. The researchers also noted the requirement for 48-week follow-up, which may have excluded patients who discontinued treatment early due to lack of efficacy. Additionally, the influence of concurrent topical therapies was not fully assessed.

References

1. Yildrim SK, Ayyildiz SM, Öğüt ND, Erbağci E, Ünal S, Gokyayla E. Predictive factors of early super-response to biologic agents in psoriasis: insights from real-world evidence. Clin Cosmet Investig Dermatol. Published online March 19, 2026. doi:10.2147/CCID.S589513

2. Chung J, Duffin KC, Takeshita J, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared to moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2014;71(4):623-632. doi:10.1016/j.jaad.2014.04.063